Integral Molecular Presents Data on Monoclonal Antibodies (MAbs) Against SLC2A4 (GLUT4),...
Integral Molecular Presents Data on Monoclonal Antibodies (MAbs) Against SLC2A4 (GLUT4), a Critical Target for Diabetes
Ocular Therapeutix Announces FDA Approval of Supplemental New Drug Application (sNDA)...
Ocular Therapeutix Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of...
Treatment targets for men with advanced prostate cancers
Treatment targets for men with advanced prostate cancers
Treatment targets for men with advanced prostate cancers
Treatment targets for men with advanced prostate cancers
Medicago Awarded “Best New Vaccine Technology/Platform” at the World Vaccine Congress
Medicago Awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress
